Company intelligence / Profile preview

Ultimovacs ASA

Ownership: Public · ZLNA.OL
Employees: ~45
Development stage: Phase 2

Overview

UV1 has demonstrated safety and immunogenicity in multiple studies. In mesothelioma, the NIPU trial showed that adding UV1 to checkpoint inhibitors was feasible as second-line treatment. Topline results from INITIUM Phase II trial in melanoma were expected March 2024. The FOCUS trial evaluated UV1 plus pembrolizumab in head & neck cancers.

Therapeutic areas: Oncology
Modalities: Peptide-based cancer vaccinesConjugation technology for drug conjugatesTCR-NK cell therapies (via Zelluna acquisition/combination)
Industry: Biotech

Drug pipeline

6 assets

UV1

5 more assets in the full pipeline.

Request access →

Partnerships

Bristol Myers Squibb (checkpoint inhibitor combo trials)Oslo University Hospital

Financials

Market cap: $623.6M
Total revenue: $0
Enterprise value: $538.4M

Beyond the preview

Go deeper on Ultimovacs ASA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ultimovacs ASA.

Explore the full profile